Literature DB >> 19041979

Bioconversion of red ginseng saponins in the gastro-intestinal tract in vitro model studied by high-performance liquid chromatography-high resolution Fourier transform ion cyclotron resonance mass spectrometry.

Hongwei Kong1, Mei Wang, Koen Venema, Annet Maathuis, Rob van der Heijden, Jan van der Greef, Guowang Xu, Thomas Hankemeier.   

Abstract

A high-performance liquid chromatography-high resolution Fourier transform ion cyclotron resonance mass spectrometry (HPLC-FTICR-MS) method was developed to investigate the metabolism of ginsenosides in in vitro models of the gastro-intestinal tract. The metabolites were identified by high-resolution tandem mass spectrometry. Degradation and bioconversion routes of the different ginsenosides at acidic (gastric) conditions and in the presence of intestinal microbiota were elaborated. Besides hydrolysis (deglycosylation) also hydration reactions occurred at acidic conditions. The results illustrate the value of metabolite profiling by HPLC-FTICR-MS for understanding of the mechanisms in bioavailability of herbal drugs and their metabolites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041979     DOI: 10.1016/j.chroma.2008.11.030

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  14 in total

Review 1.  Metabolism of ginseng and its interactions with drugs.

Authors:  Lian-Wen Qi; Chong-Zhi Wang; Guang-Jian Du; Zhi-Yu Zhang; Tyler Calway; Chun-Su Yuan
Journal:  Curr Drug Metab       Date:  2011-11       Impact factor: 3.731

Review 2.  Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides.

Authors:  Huai-You Wang; Lian-Wen Qi; Chong-Zhi Wang; Ping Li
Journal:  Am J Chin Med       Date:  2011       Impact factor: 4.667

3.  Ultra-performance liquid chromatography and time-of-flight mass spectrometry analysis of ginsenoside metabolites in human plasma.

Authors:  Chong-Zhi Wang; Karen E Kim; Guang-Jian Du; Lian-Wen Qi; Xiao-Dong Wen; Ping Li; Brent A Bauer; Marc B Bissonnette; Mark W Musch; Eugene B Chang; Chun-Su Yuan
Journal:  Am J Chin Med       Date:  2011       Impact factor: 4.667

Review 4.  Isolation and analysis of ginseng: advances and challenges.

Authors:  Lian-Wen Qi; Chong-Zhi Wang; Chun-Su Yuan
Journal:  Nat Prod Rep       Date:  2011-01-24       Impact factor: 13.423

5.  Bioactivity and bioavailability of ginsenosides are dependent on the glycosidase activities of the A/J mouse intestinal microbiome defined by pyrosequencing.

Authors:  Tao Niu; Diane L Smith; Zhen Yang; Song Gao; Taijun Yin; Zhi-Hong Jiang; Ming You; Richard A Gibbs; Joseph F Petrosino; Ming Hu
Journal:  Pharm Res       Date:  2012-12-20       Impact factor: 4.200

6.  Biotransformation of ginsenosides Rb1, Rg3 and Rh2 in rat gastrointestinal tracts.

Authors:  Tianxiu Qian; Zongwei Cai
Journal:  Chin Med       Date:  2010-05-26       Impact factor: 5.455

7.  Protopanaxadiol, an active ginseng metabolite, significantly enhances the effects of fluorouracil on colon cancer.

Authors:  Chong-Zhi Wang; Zhiyu Zhang; Jin-Yi Wan; Chun-Feng Zhang; Samantha Anderson; Xin He; Chunhao Yu; Tong-Chuan He; Lian-Wen Qi; Chun-Su Yuan
Journal:  Nutrients       Date:  2015-01-23       Impact factor: 5.717

8.  Recent methodology in ginseng analysis.

Authors:  Seung-Hoon Baek; Ok-Nam Bae; Jeong Hill Park
Journal:  J Ginseng Res       Date:  2012-04       Impact factor: 6.060

9.  Enhanced oral absorption of 20(S)-protopanaxadiol by self-assembled liquid crystalline nanoparticles containing piperine: in vitro and in vivo studies.

Authors:  Xin Jin; Zhen-hai Zhang; E Sun; Xiao-bin Tan; Song-lin Li; Xu-dong Cheng; Ming You; Xiao-bin Jia
Journal:  Int J Nanomedicine       Date:  2013-02-12

10.  Positive influence of gut microbiota on the effects of Korean red ginseng in metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Eunhak Seong; Shambhunath Bose; Song-Yi Han; Eun-Ji Song; Myeongjong Lee; Young-Do Nam; Hojun Kim
Journal:  EPMA J       Date:  2021-06-03       Impact factor: 8.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.